https://charts.traderzeitung.de/phases/US01626L2043 string(1438) "{"isin":"US01626L2043","name":"Aligos Therapeutics Inc","stock_id_xnas":65844981,"stock_id_xnys":null,"generated_at":"2026-08-09 08:04:00","days":[{"date":"2026-08-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.73,"close_at":"2026-08-05 21:37:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.734,"close_at":"2026-08-05 22:00:00","complete":true,"perf_pct":0.0846}]},{"date":"2026-08-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":4.3,"close_at":"2026-08-06 15:28:00","complete":true,"perf_pct":-9.1677},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.61,"close_at":"2026-08-06 21:59:00","complete":true,"perf_pct":30.4651},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.626,"close_at":"2026-08-07 21:59:00","complete":true,"perf_pct":0.2852},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Aligos Therapeutics Aktie News & Nachrichten

[WKN: A40LQ4 | Symbol: ALGS]

Realtimekurs

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

10J

Alles

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Aligos Therapeutics gefunden werden.

Aligos Therapeutics Nachrichtenticker öffnen

MT Newswires 13.07.2026 14:36 Uhr

Aligos Therapeutics Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Aligos Therapeutics schließt Rekrutierung in Phase-2-Studie einer potenziellen Behandlung für chronische Hepatitis B ab

Aligos erhält 25 Millionen US-Dollar Vorauszahlung aus Lizenzvertrag

Lake Street nimmt die Coverage für Aligos Therapeutics mit einer Kaufempfehlung und einem Kursziel von 45 $ auf